Associate Michael Ellenberger will lead a roundtable on "AI in Biopharmaceutical Licensing" at the Licensing Executives Society (LES) USA-Canada 2025 Annual Meeting taking place October 19-22, 2025, in Boston, Massachusetts. Michael's roundtable will take place on Monday, October 20.
Artificial intelligence (AI) is progressively playing a pivotal role in transforming the biopharmaceutical licensing landscape, influencing every stage from drug discovery to deal-making. As the USPTO and FDA issue new guidance, and the industry embraces rapid technological advancements, AI’s impact in licensing transactions has become a topic of both excitement and scepticism. Some argue that the technology may oversimplify complex human decision-making processes, while others see it as a tool that enhances human expertise. In this interactive roundtable session, we will delve into how AI is revolutionizing the licensing process, specifically its applications in due diligence, asset valuation, and contract structuring.
Michael's session will be a collaborative discussion, where attendees will have the opportunity to share their own experiences, insights, and challenges with AI in their licensing practices. Attendees will leave the roundtable session with an understanding of how AI is currently being applied in key aspects of biopharmaceutical licensing, recognizing both the significant advantages as well as the potential risks and limitations, alongside the knowledge of how to strategically incorporate AI in their licensing processes.
Licensing Executive Society USA & Canada (LES) is the original, leading professional society for intellectual property and licensing experts.
To learn more about the event, and to register, please visit the LES USA-Canada 2025 Annual Meeting webpage.
